CERo Therapeutics has dosed the seventh patient in its Phase 1 trial of CER-1236, a novel engineered T cell therapy targeting hematologic malignancies like AML, MDS, and MF. The trial is progressing without dose-limiting toxicities observed in the second cohort, and early data shows expansion of the infused cells, supporting further evaluation. The study aims to assess safety, tolerability, and preliminary efficacy, with plans to include more patients across related blood cancers. This progress marks a key step in developing a new immunotherapy that could offer benefits beyond current CAR-T treatments.
CERo Therapeutics dosing update offers context for readers. For those tracking health-sector stocks, 75 of 150 US stocks rose and 69 fell on Pluang as of Nov 03, 2026 20:11 WIB. Notable movers include INO at USD 1.77 with a -6.08% change, PHG at USD 29.00 up 5.11%, and NUVB at USD 4.81 up 4.79%.
Anavex Life Sciences appointed Terrie Kellmeyer, Ph.D., as President and CEO, also joining the Board. Kellmeyer, with over 30 years in biopharma, has led the company through key clinical milestones including FDA clearance for Fragile X syndrome trial...
Cardiff Oncology, a clinical-stage biotech company focusing on cancer therapies via PLK1 inhibition, announced it will present at the UBS Global Biopharma Conference on November 16-17, 2026. The company's CEO, Mani Mohindru, will deliver a fireside c...
Seyond Inc is enhancing its smart city solutions by integrating advanced LiDAR 3D sensing with AI-powered analytics and collaborations with Dell Technologies, NVIDIA, and AMSYS. This expansion supports improved safety, transportation, and infrastruct...
Stella-Jones Inc. announced a teleconference on November 4, 2026, at 10:00 AM EST to discuss its third-quarter 2026 financial results. The event is open to investors, analysts, and interested parties, with live streaming and phone access provided. A ...
Stella-Jones Inc. announced a conference call for November 4, 2026, at 10:00 AM EST to discuss its third quarter 2026 financial results. The call is open to investors, analysts, and interested parties and will be webcast live with a recording availab...
